LMNTD2-AS1: LMNTD2-AS1 is one of the seven candidate long non-coding RNAs (lncRNAs) found to be associated with pulmonary arterial hypertension (PAH) for the first time [PMC9779127]. It is also one of the lncRNAs whose expression data were merged with prognosis data of pancreatic cancer (PC) patients [PMC9632290]. The expression of LMNTD2-AS1 was found to be correlated with several other lncRNAs in PC patients [PMC9632290]. In a risk model for PC patients, high expression levels of LMNTD2-AS1 were associated with a significantly lower progression-free interval (PFI) compared to low expression levels [PMC9632290]. LMNTD2-AS1, along with other lncRNAs, was also found to be significantly correlated with overall survival (OS) and PFI in PC patients [PMC9632290]. The overexpression of LMNTD2-AS1 and other lncRNAs was associated with a shorter OS and PFI in PC patients [PMC9632290]. Furthermore, the overexpression levels of LMNTD2-AS1 and other lncRNAs were found to have significant value in diagnosing 1-, 3-, and 5-year survival time in PC patients [PMC9632290]. In breast cancer, LMNTD2-AS1 was highly expressed compared to normal breast tissue [PMC8521053][PMC9171493][PMC8961446][PMC9035528][PMC10057494]. Its overexpression was associated with poor prognosis for breast cancer patients [PMC9171493]. Additionally, PD-L1 expression was significantly associated with LMNTD2-AS1 expression in breast cancer cells [PMC8521053].